TNA
HQL

True North Advisors’s abrdn Life Sciences Investors HQL Stock Holding History

True North Advisors’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,075
Closed -$143K – 203
2022
Q4 		$143K Buy
+10,075
New +$146K 0.05% 164

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
CA
Cornerstone Advisors Asheville, North Carolina $2.72B AUM 22.17% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

True North Advisors's HQL Position: Q1 2023 in Review

True North Advisors sold out of abrdn Life Sciences Investors (HQL) in Q1 2023, closing a stake of 10,075 shares — an estimated $143K sold.

True North Advisors first reported a position in HQL in Q4 2022 and held it in 1 quarter. The position peaked at $143K in Q4 2022. 78 funds tracked by Wall St. Rank hold HQL as of Q1 2023.

  • True North Advisors reported no remaining abrdn Life Sciences Investors position as of Q1 2023 after selling out during the quarter.
  • True North Advisors sold 10,075 abrdn Life Sciences Investors shares in Q1 2023, an estimated $143K.
  • True North Advisors first reported a position in abrdn Life Sciences Investors in Q4 2022 and held it in 1 quarter.
  • True North Advisors's abrdn Life Sciences Investors position peaked at $143K in Q4 2022.
  • 78 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2023.

Based on True North Advisors's 13F filing for Q1 2023, filed 15 May 2023.